Phaseline

Targets › LDHA

LDHA (L-lactate dehydrogenase A chain): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Genitourinary; next expected readout Apr 2030.

Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+). Can also use 2-oxoglutarate as substrate and catalyze the reduction of 2-oxoglutarate to L-2-hydroxyglutarate. (UniProt, P00338)

Open in Phaseline: the race on LDHA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNedosiran Sodium
L-lactate dehydrogenase A chain mRNA RNAi inhibitor
LDHAPhase 3Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 1Apr 2030

Conditions

Primary Hyperoxaluria Type 1 (PH1) (1) Primary Hyperoxaluria Type 1 (1)

Modalities

other (1)

Companies

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.